Business Context and Reporting Period
Agilon health, Inc. filed a Form 8-K reporting the results of its annual meeting of stockholders held on May 24, 2023. The report was signed and dated May 25, 2023. The company’s common stock trades on the NYSE under the symbol AGL.
Voting Results
| Proposal | Result |
|---|---|
| Election of four Class II directors | Ron Williams, Derek L. Strum, Diana L. McKenzie, and Karen McLoughlin were elected to serve until the 2026 annual meeting and until their successors are elected and qualified. |
| Ratification of Ernst & Young LLP | Approved as the independent registered public accounting firm for the fiscal year ending December 31, 2023. |
| Advisory vote on executive compensation | Approved on a non-binding basis. |
Director Election Vote Detail
| Nominee | Votes For | Votes Withheld | Abstained | Broker Non-Votes |
|---|---|---|---|---|
| Ron Williams | 357,488,559 | 34,999,837 | 36,434 | 7,391,970 |
| Derek L. Strum | 364,341,351 | 28,146,544 | 36,935 | 7,391,970 |
| Diana L. McKenzie | 391,812,524 | 675,590 | 36,716 | 7,391,970 |
| Karen McLoughlin | 366,785,937 | 25,702,674 | 36,219 | 7,391,970 |
Other Voting Results
- Auditor ratification: 399,901,122 votes for, 4,777 against, and 10,901 abstentions.
- Executive compensation: 333,822,301 votes for, 58,625,836 against, 76,693 abstentions, and 7,391,970 broker non-votes.
Financial Metrics and Material Changes
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It does not report a comparable-period financial change.
Outlook, Risks, and Unusual Items
The filing contains no new management outlook, risk disclosures, contingencies, or unusual financial items. The executive compensation vote was advisory and non-binding.
Important Facts to Verify
- Confirm the elected directors’ continued service and committee assignments through the 2026 annual meeting.
- Review the definitive proxy statement dated April 14, 2023 for proposal details and compensation disclosures.
- Verify Ernst & Young LLP’s appointment and any subsequent auditor-related filings for fiscal 2023.
- Assess the level of opposition to executive compensation, including the approximately 58.6 million votes against.